Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1

Abstract

TMC114/r demonstrated statistically higher 24-week virological response rates and CD4 cell count increases than CPI(s). TMC114/r 600/100 mg twice daily has received regulatory approval in treatment-experienced patients.

Darunavir Outcomes Study: Comparative Effectiveness of Virologic Suppression, Regimen Durability, and Discontinuation Reasons for Three-Class Experienced Patients at 48 Weeks

“…The observation of lower rates of adverse events in the DRV/r and PI-Sparing treatment strategies echo the favorable safety profiles for post-2006 treatment options reported in recent clinical trials. [2][3][4][6][7][8][9][10][11][12] The results of this study should be interpreted within the context of its limitations. As a single academic HIV clinic in the Southeastern USA, results may not be generalizable to other locations.…”

“…With various clinical trials highlighting the safety and superior efficacy of these newer agents, complete virologic suppression has become the therapeutic goal for all HIV-infected patients, including those who are treatment-experienced. [1][2][3][4][5][6][7][8][9][10][11][12] Despite the accumulating body of evidence from clinical trials, a paucity of published data addressing the effectiveness of these newer agents in routine clinical care settings exists. Evaluating both the efficacy and effectiveness of newer agents is important to ensure that the results obtained from clinical trials are generalizable to populations treated through routine care.…”

Closing the door to human immunodeficiency virus

“…Moreover, data collected at week 48 further confirm the safety and efficacy of T-20 in treatment-experienced patients Trottier et al, 2005). T-20 has successfully been included into other optimized background regimens containing Tipranavir (Cahn et al, 2006;Hicks et al, 2006), Darunavir (Clotet et al, 2007;Katlama et al, 2007), Raltegravir and Etravirine Madruga et al, 2007). Although T-20 is the first HIV entry inhibitor for the treatment of AIDS patients, its preventive use is limited due to its relatively low potency, short half-life inconvenient administration, and rapid induction of drug-resistant virus.…”

Etravirine in combination with darunavir/ritonavir and optimized background regimen results in suppression of HIV replication in treatment-experienced patients

“…Treatment goals in treatment-experienced HIV-infected patients remain similar to that of treatment-naive patients, with a target of virologic suppression (plasma viral load <50 copies/ml) [4]. This has been made a realistic outcome through the advent of new antiretrovirals that either target novel sites within the viral lifecycle (enfuvirtide, raltegravir and maraviroc) or are active despite resistance to first-generation antiretroviral agents [5][6][7][8][9]. The 'next-generation' antiretroviral agents include darunavir, a protease inhibitor active in the setting of underlying resistance to other protease inhibitors, and etravirine, a new non-nucleoside reverse transcriptase inhibitor (NNRTI), which retains activity against viruses demonstrating resistance to efavirenz and nevirapine [10,11].…”